Bristol-Myers Squibb (BMY)$59.46
Market Cap: 101.88 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Bristol-Myers Squibb (BMY).
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
DCF ready
Valuation
10.6x
EV/FCF, 9.4% FCF yield
Quality
11.1%
ROIC, 26.7% FCF margin
Growth
2.5%
5Y sales (revenue) CAGR
Balance sheet
2.4x
Debt/equity, 1.3x current ratio
Superinvestors
8
Top: Richard Pzena (3.4%)
Strengths to research
- Return on equity is strong at 38.2%.
- Free cash flow margin is healthy at 26.7%.
- 8 tracked superinvestors report a position.
- 10 annual periods are available for trend analysis.
Watchouts
- Debt/equity is high at 2.4x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BMY.
Grade C
53
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| BMY Target | Bristol-Myers Squibb | $101.9B | 17.2x | 10.6x | 11.1% | 2.5% | 26.7% | N/A | N/A | N/A |
| GILD | Gilead Sciences | $128.0B | 19.8x | 15.4x | 17.9% | 3.6% | 32.1% | N/A | 1.7x | N/A |
| GSK | GSK plc | $79.0B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SNY | Sanofi Aventis | $133.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| PFE | Pfizer Inc. | $135.4B | 19.0x | 14.8x | 9.0% | 8.5% | 14.5% | N/A | N/A | N/A |
| AMGN | Amgen | $150.6B | 23.8x | 24.2x | 12.2% | 7.6% | 22.0% | N/A | 3.2x | N/A |
| MRK | Merck & Co. | $208.5B | 16.8x | 15.7x | 34.7% | 9.4% | 19.0% | N/A | N/A | N/A |
| NVS | Novartis AG | $223.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RHHVF | Roche Holdings AG DIV RT | $263.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for BMY (annual).
8 superinvestors own BMY
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Richard Pzena Hancock Classic Value | 17,095,731 | $1.0B | 3.37% | 0.0% |
| Dodge & Cox Dodge & Cox | 4,622,820 | $280M | 0.15% | 0.0% |
| John Rogers Ariel Appreciation Fund | 721,731 | $44M | 0.49% | 0.0% |
| Kahn Brothers Group Kahn Brothers Group | 170,381 | $10M | 1.83% | 0.0% |
| Bill Miller Miller Value Partners | 69,500 | $4M | 1.10% | 0.0% |
| Hillman Value Fund Hillman Value Fund | 53,102 | $3M | 2.24% | 0.0% |
| Tweedy Browne Co. Tweedy Browne Value Fund | 26,158 | $2M | 0.13% | 0.0% |
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 24,200 | $1M | 0.02% | 0.0% |